Short-acting vs long-acting: which is better
While we anticipate retatrutide being a strong option for many people seeking weight loss, it may be particularly useful for anyone who falls into one or more of these categories: Didnt respond to earlier GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Liraglutide, Zepbound, Mounjaro, etc Plateaued with other GLP-1s but still havent met your target weight Have a large body percentage of weight to lose (20% or more) Retatrutide is currently undergoing clinical trials necessary for it to obtain FDA approval (which is anticipated by summer) , so it's not yet available to be prescribed
Zepbound has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
"In radical transparency, we have beat our head against the wall at Ro over the last 12 months to try and find ways to call pharmacies for patients to find supply